Cargando…
Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8(+) T cells for...
Autores principales: | Gujar, Shashi, Pol, Jonathan G., Kim, Youra, Kroemer, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458627/ https://www.ncbi.nlm.nih.gov/pubmed/32923158 http://dx.doi.org/10.1080/2162402X.2020.1794424 |
Ejemplares similares
-
Overcoming obstacles to repurposing for neurodegenerative disease
por: Shineman, Diana W, et al.
Publicado: (2014) -
Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
por: Kellner, Christian, et al.
Publicado: (2018) -
PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012) -
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
por: van Buuren, Marit M, et al.
Publicado: (2014) -
Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
por: Gujar, Shashi, et al.
Publicado: (2018)